NJR: Nucleic Acid Amplification Assay System, Group B Streptococcus, Direct Specimen Test: FDA Product Code 510(k) Clearances, Predicate Lineage, and Recall History (2002 to 2023)
U.S. FDA CDRH three-letter product classification NJR in Microbiology (21 CFR 866.3740) reconciled across 2002 to 2023.
Review 18 FDA 510(k) clearances, 5 recalled K-numbers, and 11 cumulative 1976 to 2026 CDRH recall notices for NJR: Nucleic Acid Amplification Assay System, Group B Streptococcus, Direct Specimen Test on Predicate Ledger.
| Regulatory Metric | Verified Value |
|---|---|
| Entity Classification | FDA 3-Letter Product Code (NJR, Class 1) |
| Clinical Advisory Specialty | Microbiology (Panel MI) |
| Cleared FDA 510(k) Submissions (1976 to 2026) | 18 clearances (6 California, 33.3%) |
| Cleared 510(k)s Linked to a Recall Notice | 5 K-numbers (cohort below n >= 20 rate floor) |
| Cumulative Historical Recall Notices (1976 to 2026) | 11 notices (0 Class I, 10 Class II, 1 Class III) |
| Currently Open vs Historical Recall Status | Cumulative 1976 to 2026 FDA archive total (11 notices); verify live open vs terminated status per notice in dossier |
| Implantable and Life-Sustaining Clearances | 0 implantable (0.0%) and 0 life-sustaining |
| Median FDA 510(k) Review Duration | 123 days (90th percentile: 419 days) |
Cumulative recall counts span 1976 to 2026 across U.S. FDA CDRH and openFDA public archives and combine closed historical notices with any currently open field actions. Browse all device cohorts, 20 clinical specialties, Shared 510(k) Predicate Lineage Stage, or reconciliation methodology.
Meru AI Healthcare Data Engineering: Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI → · AI for Healthcare Practice · Healthcare Price & Patent-Cliff Crosswalk Guide.